Repligen Corporation $RGEN Shares Bought by Congress Asset Management Co.

Congress Asset Management Co. grew its position in shares of Repligen Corporation (NASDAQ:RGEN) by 0.9% during the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 1,020,907 shares of the biotechnology company’s stock after purchasing an additional 8,681 shares during the period. Repligen makes up about 1.2% of Congress Asset Management Co.’s investment portfolio, making the stock its 11th largest position. Congress Asset Management Co.’s holdings in Repligen were worth $196,249,000 at the end of the most recent reporting period.

Other large investors have also added to or reduced their stakes in the company. United Capital Financial Advisors LLC acquired a new position in Repligen in the 2nd quarter worth $380,756,000. Wasatch Advisors LP grew its stake in shares of Repligen by 27.9% during the second quarter. Wasatch Advisors LP now owns 1,590,251 shares of the biotechnology company’s stock valued at $216,974,000 after acquiring an additional 346,720 shares in the last quarter. ABS Investment Management LLC acquired a new stake in shares of Repligen during the second quarter valued at about $191,016,000. Maverick Capital Ltd. purchased a new stake in shares of Repligen during the first quarter worth about $178,946,000. Finally, Fred Alger Management LLC increased its position in shares of Repligen by 154.3% during the fourth quarter. Fred Alger Management LLC now owns 911,527 shares of the biotechnology company’s stock worth $149,363,000 after acquiring an additional 553,105 shares during the last quarter. 97.64% of the stock is owned by institutional investors and hedge funds.

Repligen Stock Performance

RGEN traded down $14.64 during trading hours on Tuesday, hitting $174.86. 1,704,621 shares of the stock were exchanged, compared to its average volume of 1,036,977. The stock has a market cap of $9.87 billion, a price-to-earnings ratio of 239.53, a price-to-earnings-growth ratio of 3.32 and a beta of 1.08. The stock has a 50-day simple moving average of $171.55 and a 200-day simple moving average of $142.00. The company has a debt-to-equity ratio of 0.26, a current ratio of 9.05 and a quick ratio of 7.64. Repligen Corporation has a 12 month low of $100.99 and a 12 month high of $198.87.

Repligen (NASDAQ:RGEN) last released its earnings results on Tuesday, July 28th. The biotechnology company reported $0.54 earnings per share for the quarter, beating the consensus estimate of $0.45 by $0.09. The firm had revenue of $204.13 million during the quarter, compared to analyst estimates of $201.59 million. Repligen had a net margin of 5.29% and a return on equity of 5.30%. The firm’s revenue for the quarter was up 11.9% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $0.26 earnings per share. Repligen has set its FY 2026 guidance at 2.030-2.090 EPS. Analysts anticipate that Repligen Corporation will post 2.06 earnings per share for the current year.

Analysts Set New Price Targets

A number of research analysts recently commented on the company. Benchmark raised Repligen from a “hold” rating to a “buy” rating and set a $185.00 price target for the company in a report on Tuesday, July 7th. JPMorgan Chase & Co. upped their target price on Repligen from $165.00 to $175.00 and gave the company an “overweight” rating in a research report on Wednesday, July 29th. Zacks Research cut Repligen from a “strong-buy” rating to a “hold” rating in a research note on Monday, September 28th. UBS Group reissued a “buy” rating on shares of Repligen in a research report on Tuesday, September 29th. Finally, Citigroup raised shares of Repligen to a “buy” rating in a report on Tuesday, July 7th. Two equities research analysts have rated the stock with a Strong Buy rating, twelve have given a Buy rating and four have issued a Hold rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $168.57.

Repligen Profile

Repligen Corporation (NASDAQ:RGEN) develops and supplies bioprocessing technologies used by biopharmaceutical manufacturers to produce biological drugs, including monoclonal antibodies, recombinant proteins, vaccines and cell and gene therapies. Its products are used throughout the manufacturing process, from laboratory and process development through commercial-scale production.

The company’s portfolio includes chromatography products and protein A ligands and resins, filtration and fluid-management systems, single-use technologies, process analytics and other consumables and equipment.